Residency · Residency · Otolaryngology

Allergic Fungal Rhinosinusitis

Overview

Allergic fungal rhinosinusitis (AFRS) is a distinct non-invasive form of chronic rhinosinusitis driven by an IgE-mediated hypersensitivity response to fungal antigens. It is characterized by thick, eosinophilic mucin (allergic mucin) with fungal elements, unilateral or asymmetric sinus opacification, and a tendency for bony expansion and erosion. Diagnosis follows the Bent-Kuhn criteria. Treatment is primarily surgical with adjunctive medical management to prevent recurrence.

Epidemiology

Accounts for 5-10% of CRS requiring surgery. Higher prevalence in warm, humid climates (southeastern United States, Mississippi River Valley, India, Middle East). Young adults; mean age at diagnosis 20-30 years, Slight male predominance, More common in immunocompetent, atopic individuals, Most patients have allergic rhinitis; many have asthma.

Pathophysiology

Non-invasive: fungi colonize the sinus lumen but do NOT invade mucosa or tissue. IgE-mediated (type I) and likely type III hypersensitivity response to fungal antigens. Common fungi: Aspergillus, Bipolaris, Curvularia, Alternaria, Fusarium (dematiaceous/dark-walled fungi predominate). Inflammatory cascade: Fungal antigens trigger IgE-mediated mast cell degranulation. Eosinophil recruitment and degranulation. Production of thick, tenacious eosinophilic (allergic) mucin. Mucin accumulates, causing sinus expansion and bony remodeling/erosion. Expansion can extend into orbit or anterior cranial fossa.

Diagnostic Criteria (Bent-Kuhn)

All five criteria must be met for definitive diagnosis: Type I hypersensitivity (confirmed by skin prick testing or specific IgE to fungal antigens). Nasal polyposis. Characteristic CT findings (see below). Eosinophilic mucin without tissue invasion (allergic mucin on histology). Positive fungal stain or culture from surgical specimen.

Clinical Presentation

Progressive unilateral or asymmetric nasal obstruction, Rhinorrhea (thick, dark, peanut butter-like mucus), Facial pressure or proptosis (if orbital extension), Anosmia/hyposmia, Visual changes (rare; orbital or optic nerve compression), Often a young adult with known allergies, May have history of prior sinus surgery with recurrence.

Imaging

CT Sinus

Unilateral or asymmetric, expansile sinus opacification. Heterogeneous signal: central areas of hyperattenuation (metallic density) within the mucin due to concentrated metals (iron, manganese) and desiccated proteins in allergic mucin. Bony expansion and remodeling (not destruction -- key distinction from malignancy). Bony erosion may occur, including lamina papyracea, skull base, or posterior maxillary wall. Typically involves multiple sinuses on one side (pansinusitis pattern).

MRI

T1: intermediate to low signal of mucin. T2: characteristically low signal (signal void) centrally due to desiccated, protein-rich mucin with high metal content. This T2 signal void on MRI with high density on CT is nearly pathognomonic. Peripheral enhancement of inflamed mucosa. Helps differentiate from tumor and assess intracranial extension.

Histopathology

Allergic Mucin

Laminated eosinophilic mucin with dense eosinophil infiltration. Charcot-Leyden crystals (eosinophil granule breakdown products). Scattered fungal hyphae within the mucin (non-invasive; NOT within tissue). No tissue invasion, granuloma formation, or necrosis (distinguishes from invasive fungal sinusitis).

Fungal Staining

GMS (Grocott methenamine silver) or PAS stain to highlight fungal elements. Fungal cultures often positive but may be negative; culture is less sensitive than histology. Species identification usually dematiaceous fungi (Bipolaris, Curvularia).

Differential Diagnosis

Eosinophilic mucin rhinosinusitis (EMRS): allergic mucin present but no fungal elements; may represent a spectrum with AFRS. Mycetoma (fungal ball): non-invasive; dense fungal concretion without eosinophilic mucin; usually unilateral maxillary; older patients; non-atopic. Invasive fungal sinusitis (acute or chronic): tissue invasion present; immunocompromised patients; very different management. Sinonasal tumor (especially if unilateral with bony erosion). CRSwNP (bilateral, symmetric).

Treatment

Surgical Management

FESS is the primary treatment: complete removal of allergic mucin and polyps from all involved sinuses. Goals: evacuate allergic mucin, restore ventilation and drainage, allow access for topical therapy. Wide sinusotomies recommended for postoperative irrigation access and surveillance. Surgery alone does NOT address the underlying immune hypersensitivity -- recurrence is the rule without adjunctive therapy. Recurrence rates without medical therapy: 50-100%.

Postoperative Medical Management

Topical nasal corticosteroids: daily indefinitely. Topical steroid irrigations: budesonide 0.5 mg in 240 mL saline; improves mucosal inflammation and reduces recurrence. Saline irrigation: high-volume daily; washes out residual mucin and fungal antigens. Systemic corticosteroids: short courses for recurrence or perioperatively; taper over 2-4 weeks. Immunotherapy: subcutaneous or sublingual immunotherapy directed at identified fungal allergens. Evidence suggests reduced recurrence and need for revision surgery. Not universally adopted; some concern about theoretical worsening of immune response (not borne out in studies). Antifungal agents: NOT routinely recommended; AFRS is an immune-mediated (not infectious) process; topical antifungals have shown no consistent benefit in trials. Biologics: emerging role; dupilumab and omalizumab may benefit refractory AFRS given the eosinophilic/IgE-driven pathophysiology; limited direct evidence.

Monitoring and Follow-Up

Regular endoscopic surveillance: every 3-6 months initially. Look for recurrent eosinophilic mucin accumulation, polyp regrowth. In-office debridement of early recurrence. Serum total IgE trending: some use as a marker for disease activity (rising IgE may herald recurrence). Long-term follow-up essential; AFRS is a chronic, relapsing condition.

<image>Coronal CT scan of the paranasal sinuses in a patient with allergic fungal rhinosinusitis showing unilateral (left-sided) pansinusitis with expansile opacification. The central areas of hyperattenuation (metallic density) within the sinus contents are highlighted, representing desiccated allergic mucin with concentrated metal content. Bony expansion of the ethmoid and maxillary sinuses is visible with thinning of the lamina papyracea and orbital floor. Labels indicate the allergic mucin, expanded sinus walls, and the contralateral normal sinuses for comparison.</image>

<image>Histopathologic slide of allergic mucin at high power (H&E stain) showing the characteristic features of AFRS: laminated layers of eosinophilic mucin with dense eosinophil infiltration and scattered Charcot-Leyden crystals. An inset panel shows GMS (silver) stain highlighting non-invasive fungal hyphae (darkly stained) within the mucin but not invading the underlying sinus mucosa. The distinction between luminal fungal colonization and tissue invasion is annotated.</image>

<image>MRI of allergic fungal rhinosinusitis showing the characteristic T2 signal void. Left panel: T1-weighted image showing intermediate signal within the affected sinuses. Right panel: T2-weighted image showing central low signal (signal void) within the sinus contents surrounded by a rim of high-signal inflamed mucosa. The signal void pattern on T2 is contrasted with the expected high T2 signal of simple retained secretions or mucocele in a comparison diagram. Clinical significance: the T2 signal void combined with CT hyperattenuation is nearly pathognomonic for AFRS.</image>

Clinical Pearls

AFRS is non-invasive: fungi do NOT invade tissue; the disease is driven by the immune response to fungal antigens. The central hyperattenuation on CT + T2 signal void on MRI is nearly pathognomonic for AFRS -- learn to recognize this pattern. Unilateral or markedly asymmetric sinus disease in a young atopic patient should raise suspicion for AFRS. Bony erosion in AFRS is due to pressure remodeling from expanding mucin, not malignant destruction -- but always biopsy to exclude neoplasm. Surgery is necessary but insufficient: without ongoing medical therapy, recurrence is nearly universal. Antifungals are NOT indicated because AFRS is immunologic, not infectious. Immunotherapy directed at fungal allergens is a logical adjunct and appears to reduce recurrence, though evidence is still accumulating. Rising serum total IgE after surgery may signal early recurrence before it is clinically apparent. Always check for Onodi cells and skull base dehiscence on preoperative CT, as the expansile process may thin critical structures.

References

• Bent JP, Kuhn FA. "Diagnosis of allergic fungal sinusitis." Otolaryngol Head Neck Surg. 1994;111(5):580-588.
• Schubert MS. "Allergic fungal sinusitis: pathophysiology, diagnosis and management." Med Mycol. 2009;47(Suppl 1):S324-S330.
• Gan EC, Thamboo A, Rudmik L, et al. "Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery." Int Forum Allergy Rhinol. 2014;4(2):125-130.
• Tyler MA, Russell CB, Smith DE, et al. "Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes." J Allergy Clin Immunol. 2017;139(3):1111-1116.

Read this lecture as Markdown